These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 8681493)

  • 21. Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects.
    Iyer GR; Reinhard JF; Oshana S; Kauffman M; Donahue S
    J Clin Pharmacol; 2007 Jul; 47(7):817-24. PubMed ID: 17495280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of 50mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep-deprived subjects.
    Patat A; Rosenzweig P; Miget N; Allain H; Gandon JM
    Fundam Clin Pharmacol; 1999; 13(5):582-94. PubMed ID: 10520732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute tolerance to triazolam during continuous and step infusions: estimation of the effect offset rate constant.
    Kroboth PD; Bertz RJ; Smith RB
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1047-55. PubMed ID: 8450449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects.
    Mattila MJ; Patat A; Seppälä T; Kalska H; Jalava ML; Vanakoski J; Lavanant C
    Eur J Clin Pharmacol; 1996; 51(2):161-6. PubMed ID: 8911882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic metabolism of the new antipsychotic agent, mazapertine, in rat--API-MS/MS identification of metabolites.
    Wu WN; McKown LA; Reitz AB
    Eur J Drug Metab Pharmacokinet; 2003; 28(4):279-86. PubMed ID: 14743969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary human pharmacokinetics of triletide.
    Repossini L
    Pharmatherapeutica; 1985; 4(3 Spec No):189-94. PubMed ID: 4059299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects.
    Skrumsager BK; Christensen JV; Snel S; Seiberling M
    Psychopharmacology (Berl); 1995 Oct; 121(3):294-9. PubMed ID: 8584609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tiaspirone in schizophrenia.
    Moore NC; Meyendorff E; Yeragani V; LeWitt PA; Gershon S
    J Clin Psychopharmacol; 1987 Apr; 7(2):98-101. PubMed ID: 3294920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia.
    Cantillon M; Ings R; Bhat L
    Clin Transl Sci; 2018 Jul; 11(4):387-396. PubMed ID: 29637739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacological studies on centpropazine--a new antidepressant compound.
    Gupta PP; Asthana OP; Tangri AN; Dhawan BN
    Indian J Med Res; 1989 Oct; 90():360-2. PubMed ID: 2628304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects.
    Søgaard U; Michalow J; Butler B; Lund Laursen A; Ingersen SH; Skrumsager BK; Rafaelsen OJ
    Int Clin Psychopharmacol; 1990 Oct; 5(4):237-51. PubMed ID: 2150527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The preclinical discovery and development of cariprazine for the treatment of schizophrenia.
    Wesołowska A; Partyka A; Jastrzębska-Więsek M; Kołaczkowski M
    Expert Opin Drug Discov; 2018 Aug; 13(8):779-790. PubMed ID: 29722587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of RP5063 Following Single Doses to Normal Healthy Volunteers and Multiple Doses Over 10 Days to Stable Schizophrenic Patients.
    Cantillon M; Ings R; Bhat L
    Clin Transl Sci; 2018 Jul; 11(4):378-386. PubMed ID: 29119704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of acute tolerance development to the subjective, cognitive, and psychomotor effects of nitrous oxide in healthy volunteers.
    Yajnik S; Zacny JP; Young CJ; Lichtor JL; Rupani G; Klafta JM; Coalson DW; Apfelbaum JL
    Pharmacol Biochem Behav; 1996 Jun; 54(2):501-8. PubMed ID: 8743615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute clinical tolerance of creatinol O-phosphate.
    Melloni GF; Minoja GM; Lureti GF; Merlo L; Pamparana F; Brusoni B
    Arzneimittelforschung; 1979; 29(9a):1447-9. PubMed ID: 575490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple-dose pharmacokinetics and safety of a potential memory-enhancing compound, CL 275,838, in healthy male volunteers.
    Caccia S; Confalonieri S; Guiso G; Lucca U; Parma E; Guido M; Tettamanti M; Tiraboschi P; Spagnoli A
    J Clin Pharmacol; 1994 Jul; 34(7):748-53. PubMed ID: 7929869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antipsychotic medication effects on neuropsychological functions.
    Bilder RM; Turkel E; Lipschutz-Broch L; Lieberman JA
    Psychopharmacol Bull; 1992; 28(4):353-66. PubMed ID: 1363583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerance to repeated nicotine administration on performance, subjective, and physiological responses in nonsmokers.
    Heishman SJ; Henningfield JE
    Psychopharmacology (Berl); 2000 Oct; 152(3):321-33. PubMed ID: 11105943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plafibride tolerance trial at increasing doses in healthy volunteers.
    Dalmau J; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1840-4. PubMed ID: 7198462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychometric studies of pirenzepine.
    Kuhn E; Honzák R
    Scand J Gastroenterol Suppl; 1980; 66():47-53. PubMed ID: 6941377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.